PF-Atlas › Clinical Trials › NCT02212587

Tobramycin Inhalation Powder in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex

TOBI · Phase 1

Registry ID

NCT02212587

Phase

Phase 1

Status

Completed

Drug / intervention

TOBI

Sponsor

Unity Health Toronto

Start

2014-09

Enrollment

Locations

About this trial

The objective of this study is to determine if tobramycin inhalation powder (TIP) can reduce the amount of Burkholderia Cepacia Complex (BCC) species - type of bacteria, in the sputum of cystic fibrosis patient.

View NCT02212587 on ClinicalTrials.gov →

Explore related

All TOBI trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT02212587 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.